Home >Technologies Available >Technologies available for licensing

Designer Cytotoxic T cells: Transcription Factor-Based Engineering with FOSL1

Image from Licence Details: Designer Cytotoxic T cells: Transcription Factor-Based Engineering with FOSL1

Applications: Immunotherapy, Adoptive Cell Therapy (e.g. CAR-T, TCR-T, TILs)

This technology leverages a transcription factor, FOSL1, overexpressed to enhance T-cell function, boosting tumour-killing efficiency and engagement. It presents a promising advancement for adoptive therapies like CAR-T, TCR-T, and TIL, with broad applications in cancer treatment.

Features Benefits
  • Enhanced cytotoxicity.
  • Destroy tumour cells faster and more effectively, enabling better cancer clearance.
  • Increased T-cell engagement.
  • Improved cytokine production and expression of tissue homing receptors.
  • Safety profile.
  • FOSL1 overexpression does not result in non-specific activation – cytotoxicity is triggered only upon tumour engagement.
  • Versatility and scalability.
  • Can integrate with existing T-cell therapies (e.g., CAR-T, TCR-T, TIL).

 

Patent pending and available for:

  • Licensing
  • Co-development
  • Consulting
Request more information
about this technology

Back to Technologies Available

Sparks Background Image

Ready to get in touch?

Contact Us
Sparks Background Image
© Oxford University Innovation